ERBB2 and breast carcinoma: For example, to understand the heterogeneity of breast cancer and to develop personalized treatment for breast cancer [11, 14], the biomarker information that determines the subtypes of breast cancer samples, such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status, are normally required.